PETALING JAYA: DKSH Business Unit Healthcare has entered into a strategic partnership with Osteopore Ltd to enhance the distribution, commercial coverage and operational excellence of its dental solutions in Malaysia.
Through the collaboration, DKSH will support the nationwide distribution of Osteopore’s advanced dental products, expanding access to innovative regenerative technologies for dental professionals across the country.
DKSH will also provide full market expansion services, including sales, marketing, distribution and logistics, as well as customer engagement and channel management, to drive Osteopore’s growth across key healthcare and dental channels.
The partnership builds on DKSH’s strong track record in healthcare distribution and its role as a trusted partner to leading medical technology and life sciences companies.
By combining Osteopore’s product innovation with DKSH’s extensive commercial capabilities, both organisations aim to accelerate market adoption and enhance standards of care in dental and regenerative medicine.
Osteopore CEO Dr Yujing Lim said they look forward to their partnership with DKSH Malaysia, shortly after the clinical study comparing Osteopore’s polycaprolactone membrane with a collagen membrane.
“With local clinical data being generated by the leading research university hospital, University Malaysia (UM) in Malaysia, we can expect to leverage the clinical outcomes to support in-market adoption.
“As we continue to realign and strengthen our sales and distribution channels in a progressive and organised manner, we look forward to a strong partnership with DKSH Malaysia to introduce a technology that is experiencing growing traction in the market,” he said in a statement.
DKSH Business Unit Healthcare is a global leader in 3D-printed biomimetic and bioresorbable implants, while Osteopore is a leading partner for companies seeking to grow their healthcare business in Asia.
DKSH Malaysia vice-president, healthcare and head, country leadership, Sandeep Tewari said Osteopore’s technology has the potential to be first-in-class in Malaysia, and we are excited to support the launch of this innovative solution and make it accessible to healthcare professionals and patients across the market.
“Clinicians within our network have expressed strong interest in Osteopore’s products, especially when bone regrowth and augmentation are required.
“This partnership reinforces DKSH’s commitment to providing healthcare for all by delivering advanced medical innovations that elevate the standard of care across Malaysia,” he said.
Together, DKSH and Osteopore and DKSH Malaysia are committed to driving strong and sustainable growth for the brand, supported by increasing clinical adoption and expanding market reach nationwide, providing healthcare for all.